Linked Life Data

1981104

Source:http://linkedlifedata.com/resource/pubmed/id/1981104

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1991-3-28
pubmed:abstractText
Amnesia, relaxation, and cooperation, not anaesthesia, should be the clinical end points when using intravenous sedative drugs for endoscopic procedures. Diazepam has now been replaced by midazolam as the first-choice sedative agent to achieve these effects. Midazolam, when used in correct doses, is more suited to endoscopy than diazepam because of its shorter elimination half-life, larger volume of distribution, and faster total body clearance. Midazolam is also clinically superior, as it achieves amnesia in twice as many patients and at lighter levels of sedation than with diazepam. The routine use of opioids in combination with benzodiazepines is to be avoided, as it increases the likelihood of adverse cardiopulmonary events. The availability of the specific benzodiazepine antagonist, flumazenil, is not an excuse for the administration of excessive doses of benzodiazepines. Flumazenil is an essential emergency drug when benzodiazepine-induced sedation is used. Reversing single-dose benzodiazepine-induced sedation after outpatient endoscopy enables earlier accurate retention of information and earlier discharge and may have significant cost-benefit implications.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0085-5928
pubmed:author
pubmed:issnType
Print
pubmed:volume
179
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
7-11
pubmed:dateRevised
2008-2-13
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Which agent and how to deliver it? A review of benzodiazepine sedation and its reversal in endoscopy.
pubmed:affiliation
University Dept of Surgery, Manchester Royal Infirmary, UK.
pubmed:publicationType
Journal Article